<DOC>
	<DOCNO>NCT02580045</DOCNO>
	<brief_summary>This clinical trial do learn different type cancer treatment affect cancer cell spread brain . Many cancer treatment able make way brain spinal fluid central nervous system . This cross call `` blood-brain barrier '' `` BBB '' . The BBB like protective shield allow certain material pass reach brain others . This study initiate help researcher learn type cancer treatment make BBB attack cancer cell within brain , treatment make BBB . Learning may help future researcher develop effective cancer drug well fight cancer cell spread brain .</brief_summary>
	<brief_title>Pharmacokinetics Systemic Anti-Cancer Therapies Cerebrospinal Fluid ( CSF ) Patients With Advanced Cancer</brief_title>
	<detailed_description>Very little known penetration systemic therapy normal blood brain barrier way brain metastasis radiation would impact permeability blood brain barrier . This study would one first examine concentration systemic cancer therapy cerebrospinal fluid ( CSF ) match serum sample . Additionally , concentration therapy brain metastasis surgical specimen would particular interest correlate serum CSF level , length time therapy , latency develop brain metastasis future study . As participant study , patient schedule lumbar puncture per standard care treatment subject withdrawal 15cc 's cerebrospinal fluid pharmacokinetic analysis . They also blood draw 5mL within 2 hour lumbar puncture serum pharmacokinetics . If patient eligible elect proceed surgical resection brain metastasis , optional CSF serum sample would draw time resection .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<criteria>1 . Metastatic cancer patient systemic anticancer therapy ( chemotherapy , endocrine therapy , HER2 target therapy , immune therapy ) . 2 . Patients must able lumbar puncture within 2 halflives last dose systemic therapy . 3 . Patients undergo LP reason know advanced cancer systemic anticancer therapy eligible . 4 . Patients new previously treat brain metastasis eligible . 5 . Patients may receive prior stereotactic radiosurgery brain and/or whole brain radiation . 6 . No limitation prior systemic intrathecal therapy . 7 . There restriction systemic therapy enrollment . 8 . Laboratory criterion : normal renal function : creatinine &lt; 1.5 x upper limit normal ( ULN ) ) , liver function : bilirubin &lt; 1.5 x ULN , transaminases &lt; 2 x ULN , except know hepatic disease , wherein may &lt; 5 x ULN , blood count : WBC ≥ 2.0 , Neutrophils ≥1500 , platelets ≥100,000 , Hemoglobin ≥ 10 . 9 . Age &gt; 18 year 10 . Patients must ability give informed consent . 11 . Patients must sign informed consent form prior enrollment study . 1 . No history lumbar surgery preexist spinal condition would preclude safe , reliable lumbar puncture . 2 . Patients significant psychiatric illness medical illness would preclude ability comply protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>metastatic cancer</keyword>
	<keyword>lumbar puncture</keyword>
	<keyword>advanced cancer</keyword>
	<keyword>brain metastasis</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>endocrine therapy</keyword>
	<keyword>HER2 target therapy</keyword>
	<keyword>immune therapy</keyword>
	<keyword>anti-cancer therapy</keyword>
	<keyword>blood brain barrier</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>Duke University</keyword>
	<keyword>brain metastasis</keyword>
</DOC>